Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Palliative therapy: extensive small cell lung cancer

P J Loehrer1

  • 1Indiana University School of Medicine, Indiana University Hospital, Indianapolis 46202-5265, USA.

Seminars in Oncology
|April 1, 1995
PubMed
Summary

Systemic chemotherapy offers objective responses in most small cell lung cancer patients. However, prolonged survival remains a challenge, especially for extensive disease, necessitating a balance of treatment benefits and costs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Kenya cancer research and control stakeholder program: Evaluating a bilateral partnership to strengthen national cancer efforts.

Journal of cancer policy·2023
Same author

A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women.

BMC infectious diseases·2019
Same author

Building cancer nursing skills in a resource-constrained government hospital.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2012
Same author

A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancer.

Urologic oncology·2011
Same author

HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation.

British journal of cancer·2005
Same author

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2004

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Treatments

Background:

  • Significant advancements in systemic treatment for small cell lung cancer (SCLC) have occurred over the last two decades.
  • While chemotherapy yields objective responses in the majority of SCLC patients, prolonged survival, particularly in extensive disease, remains limited.

Purpose of the Study:

  • To review the efficacy of systemic chemotherapy regimens in small cell lung cancer.
  • To evaluate the potential of single-agent chemotherapy as an alternative treatment approach.
  • To emphasize the importance of balancing therapeutic benefits with treatment costs for palliative care in extensive SCLC.

Main Methods:

  • Review of clinical trials and treatment outcomes for small cell lung cancer over the past twenty years.
  • Analysis of response rates and survival data for combination chemotherapy regimens (e.g., cyclophosphamide/doxorubicin/vincristine, cisplatin/etoposide, cisplatin/etoposide/ifosfamide).
  • Consideration of recent findings from single-agent chemotherapy trials.

Main Results:

  • Combination chemotherapy regimens achieve objective responses in 55% to 65% of small cell lung cancer patients.
  • Recent clinical trials indicate that single-agent chemotherapy may offer survival durations comparable to combination therapies.
  • The findings suggest single-agent chemotherapy could be a viable option, particularly for elderly patients.

Conclusions:

  • Systemic chemotherapy has improved response rates in small cell lung cancer, but long-term survival for extensive disease is still a significant challenge.
  • Single-agent chemotherapy presents a potentially comparable alternative to combination regimens, warranting further investigation in prospective trials.
  • Optimizing palliative benefit in extensive SCLC requires a comprehensive assessment of treatment efficacy against physical, psychological, and financial costs.

Related Experiment Videos